Thierry Kuntzer

Thierry Kuntzer

Auto-generated profile, based on publicly available information

Thierry Kuntzer

CHU Vaudois and University of Lausanne; Nerve-Muscle Unit, Service of Neurology; Lausanne Switzerland 1011

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2019 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
FMFilipe Martins
Filipe Martins
LSLatifyan Sofiya
Latifyan Sofiya
Gerasimos SykiotisGerasimos Sykiotis
Gerasimos Sykiotis
FLFaiza Lamine
Faiza Lamine
MMMichel Maillard
Michel Maillard
MOMichel Obeid
Michel Obeid

5 May 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
EMEmma Matthews
Emma Matthews
RBRuth Brassington
Ruth Brassington
TKThierry Kuntzer
Thierry Kuntzer
FJFatima Jichi
Fatima Jichi
AMAdnan Y Manzur
Adnan Y Manzur

23 January 2008
Verified
Reference Entry
Closed access
PDF file
AMAdnan Y Manzur
Adnan Y Manzur
TKThierry Kuntzer
Thierry Kuntzer
MPMike Pike
Mike Pike
ASAnthony V Swan
Anthony V Swan

1 November 2003 in Pain
Verified
Journal Article
Closed access
TMTorsten Meier
Torsten Meier
GWGunnar Wasner
Gunnar Wasner
MFMarkus Faust
Markus Faust
TKThierry Kuntzer
Thierry Kuntzer
FOFrançois Ochsner
François Ochsner
RBRalf Baron
Ralf Baron
Peripheral neuropathic pain syndromes (PNPS) are difficult to treat because commonly used analgesics are often ineffective when, for example, touch-evoked allodynia, hyperalgesia, and pain paroxysms are present. To investigate whether lidocaine patch 5% treatment is also effective in postherpetic neuropathy (PHN) and in other PNPS, 40 patients with various forms and localizations of PNPS completed a prospective, randomized, placebo-controlled, two-way, cross-over study in three medical hospitals. Patients suffering from pain in a localized skin area with intensity above 40 mm visual analog scale (VAS) and a stable consumption of pain medication were included in this study. The study was divided into four phases: 3-day run-in phase, treatment phase 1, wash-out period, and treatment phase 2, each lasting 1 week. At the discretion of the patients, up to four patches (covering a maximum of 560 cm2) were applied onto the maximally painful area for 12 consecutive hours daily, always either by day or at night. Throughout the four phases, ongoing pain, allodynia, quality of neuropathic symptoms, quality of sleep, and adverse events were assessed. When, after the wash-out period, the pain intensity scores did not return to the pre-treatment values (+/-20%), these patients were excluded from the study. The present study revealed that, as an add-on therapy, the lidocaine patch 5% was clearly effective in reducing ongoing pain (P=0.017) and allodynia (P=0.023) during the first 8 h after application and that the patches also worked well over a period of 7 days (P=0.018) in diverse focal PNPS. Calculation of the numbers needed to treat (NNT) to obtain one patient with more than 50% relief of ongoing pain revealed that the NNT of 4.4 in the present study compared reasonably well with other studies of PHN, such as topically applied capsaicin (NNT: 5.3-infinity) or systemic treatment with gabapentin (NNT: 3.2-5.0).

1 August 2009 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
CHCaroline Huzé
Caroline Huzé
SBStéphanie Bauché
Stéphanie Bauché
PRPascale Richard
Pascale Richard
FCFrédéric Chevessier
Frédéric Chevessier
EGEvelyne Goillot
Evelyne Goillot
DHDaniel Hantaï
Daniel Hantaï

6 August 2004 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
TKThierry Kuntzer
Thierry Kuntzer
JAJean‐Christophe Antoine
Jean‐Christophe Antoine
ASAndreas J. Steck
Andreas J. Steck